Floatz logo

Enzalutamide

Progesterone Receptor Negative

Vanderbilt-Ingram Cancer CenterSmall moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Progesterone Receptor Negative cohort.

Asset / SponsorPhaseRating
Carboplatin
Northwestern University
Phase 3BBB
Epirubicin
Massachusetts General Hospital
Phase 2BB
Pembrolizumab
Massachusetts General Hospital
Phase 2BB
Cyclophosphamide
Massachusetts General Hospital
Phase 3BB
Inno-206
Roswell Park Cancer Institute
Phase 3BB

View all 50 →

Same molecule, other indications

Enzalutamide is also rated in:

Metastatic Castration Resistant Prostate CancerDormant
BBB
Indicative ·
77 / 100
View asset →
prostate carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
castration-resistant prostate carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →